In-situ Tumor Vaccination: Bringing the Fight to the Tumor

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2015 Jun 10

PMID 26055074

Citations 36

Authors

Robert H Pierce

Jean S Campbell

Sara I Pai

Joshua D Brody

Holbrook E K Kohrt

Affiliations

Soon will be listed here.

Abstract

After decades of development in the shadow of traditional cancer treatment, immunotherapy has come into the spotlight. Treatment of metastatic tumors with monoclonal antibodies to T cell checkpoints like programed cell death 1 (PD-1) or its ligand, (PD-L1), have resulted in significant clinical responses across multiple tumor types. However, these therapies fail in the majority of patients with solid tumors, in particular those who lack PD1(+)CD8(+) tumor-infiltrating lymphocytes within their tumors. Intratumoral "in situ vaccination" approaches seek to enhance immunogenicity, generate tumor infiltrating lymophcytes (TIL) and drive a systemic anti-tumor immune response, directed against "unvaccinated," disseminated tumors. Given the emerging picture of intratumoral immunotherapy as safe and capable of delivering systemic efficacy, it is anticipated that these approaches will become integrated into future multi-modality therapy.

Citing Articles

Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to vaccination.

Ursic Valentinuzzi K, Kamensek U, Brezar S, Heranney C, Komel T, Bucek S Front Immunol. 2025; 16:1470432.

PMID: 40007542 PMC: 11850275. DOI: 10.3389/fimmu.2025.1470432.

An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.

Dai J, Zhu J, Zhu L, Wang X, Bao J, Chen X Future Oncol. 2024; 20(20):1393-1400.

PMID: 39034683 PMC: 11376417. DOI: 10.1080/14796694.2024.2357063.

Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches.

Elzoghby A, Samir O, Emam H, Soliman A, Abdelgalil R, Elmorshedy Y Acta Pharm Sin B. 2024; 14(6):2475-2504.

PMID: 38828160 PMC: 11143780. DOI: 10.1016/j.apsb.2024.03.022.

The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers.

Saidian A, Dolendo I, Sharabi A, Stewart T, Rose B, McKay R Cancers (Basel). 2023; 15(1).

PMID: 36612124 PMC: 9818005. DOI: 10.3390/cancers15010127.

Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.

Walters A, Ali A, Wang J, Al-Jamal K Drug Deliv Transl Res. 2022; 13(7):2032-2040.

PMID: 36417163 PMC: 10238356. DOI: 10.1007/s13346-022-01258-8.

References

Rook A, Kubin M, Cassin M, Vonderheid E, Vowels B, Wolfe J . IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol. 1995; 154(3):1491-8. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Atkins M, Robertson M, Gordon M, Lotze M, Decoste M, DUBOIS J . Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997; 3(3):409-17. View

Dewan M, Galloway A, Kawashima N, Dewyngaert J, Babb J, Formenti S . Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15(17):5379-88. PMC: 2746048. DOI: 10.1158/1078-0432.CCR-09-0265. View

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

Brody J, Ai W, Czerwinski D, Torchia J, Levy M, Advani R . In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; 28(28):4324-32. PMC: 2954133. DOI: 10.1200/JCO.2010.28.9793. View

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

Degryse S, de Bock C, Cox L, Demeyer S, Gielen O, Mentens N . JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014; 124(20):3092-100. DOI: 10.1182/blood-2014-04-566687. View

10.

Leonard J, Sherman M, Fisher G, Buchanan L, Larsen G, Atkins M . Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90(7):2541-8. View

11.

Swanson M, Sinha U . Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Oral Oncol. 2014; 51(1):12-5. DOI: 10.1016/j.oraloncology.2014.10.010. View

12.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

13.

Yu Z, Theoret M, Touloukian C, Surman D, Garman S, Feigenbaum L . Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest. 2004; 114(4):551-9. PMC: 503773. DOI: 10.1172/JCI21695. View

14.

Lugade A, Sorensen E, Gerber S, Moran J, Frelinger J, Lord E . Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008; 180(5):3132-9. DOI: 10.4049/jimmunol.180.5.3132. View

15.

ODay S, Maio M, Chiarion-Sileni V, Gajewski T, Pehamberger H, Bondarenko I . Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21(8):1712-1717. DOI: 10.1093/annonc/mdq013. View

16.

Crittenden M, Thanarajasingam U, Vile R, Gough M . Intratumoral immunotherapy: using the tumour against itself. Immunology. 2004; 114(1):11-22. PMC: 1782057. DOI: 10.1111/j.1365-2567.2004.02001.x. View

17.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A . STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014; 41(5):843-52. PMC: 5155593. DOI: 10.1016/j.immuni.2014.10.019. View

18.

Huppa J, Davis M . T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003; 3(12):973-83. DOI: 10.1038/nri1245. View

19.

Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P . Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014; 4(6):674-87. DOI: 10.1158/2159-8290.CD-13-0458. View

20.

Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I . Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol. 2004; 22(8):1389-97. DOI: 10.1200/JCO.2004.04.059. View